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complications with the use of prophylactic fonda-
parinux in older patients and those with reduced 
renal function because of the renal clearance of the 
drug. The best information regarding this comes 
from the Arixtra for Thromboembolism Preven-
tion in a Medical Indications Study (ARTEMIS),3 
which included 849 subjects with a mean age of 
75 years who were randomly assigned to receive 
prophylaxis with fondaparinux or placebo. Patients 
with severely reduced renal function (serum creat-
inine, >180 μmol per liter) were excluded. The 
rate of major bleeding in both treatment groups 
was low, at 0.2%. This indicates that fondapari-
nux has a favorable balance of benefit to risk but 
should be avoided in patients with severe renal 
compromise. Famularo et al. also raise the issue 
of cost, which can be an important determinant 
in drug choice. However, the cost varies from one 
market to another and changes with competition, 
as new drugs become available.
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Somatic SDHB Mutation in an Extraadrenal 
Pheochromocytoma
To the Editor: As many as 25% of pheochromo-
cytomas — catecholamine-producing tumors lo-
cated along the sympathetic nervous system, in-
cluding the adrenals — occur in hereditary tumor 
syndromes that include von Hippel–Lindau disease 
(VHL gene),1 multiple endocrine neoplasia type 2 
(RET gene), neurofibromatosis type 1 (NF1 gene), 
and the pheochromocytoma–paraganglioma syn-
drome (SDHB and SDHD genes). The last two genes 
are also associated with extraadrenal pheochromo-
cytoma.2,3 To date, except for one sporadic SDHD 
mutation, only germ-line mutations in SDHB and 
SDHD have been described, even among reported 
mutations in these genes in apparently sporadic 
pheochromocytomas and paragangliomas.4,5
We present a case of a 25-year-old woman with 
an extraadrenal pheochromocytoma in the wall of 
her urinary bladder. Mutational analysis of the 
pheochromocytoma candidate genes RET, VHL, 
SDHB, and SDHD was performed in tumor and nor-
mal DNA present in the same tissue specimen. 
(The NF1 gene was not investigated, since the pa-
tient had no clinical signs of neurofibromatosis 
type 1 disease.) A single aberration was found: 
an SDHB 299C→T transition in tumor DNA but 
not in the patient’s normal DNA (Fig. 1A and 1B). 
This finding was confirmed by allelotyping the 
DNA samples and repeating the entire procedure, 
starting with the isolation of DNA from tumor 
and normal tissue. This somatic SDHB gene mu-
tation results in a substitution of phenylalanine 
for serine at position 100 (S100F). Functional 
consequences of the S100F mutation can be an-
ticipated, given the large physical differences be-
tween the two amino acids: substitution of a 
nonpolar side chain (F) for an uncharged polar 
side chain (S). In addition, the region of the 
SDHB gene that includes the S100F mutation is 
highly conserved at the protein level. Moreover, 
an SDHB germ-line missense mutation of the 
S100 neighboring amino acid (C101Y) has been 
described in a patient with an extraadrenal 
pheochromocytoma.1
From the sequence analysis of the tumor DNA, 
it is apparent that the mutated allele is in excess 
of the wild-type allele (Fig. 1A), indicating ampli-
fication of the mutated allele or loss of the wild-
type allele. Comparative genomic hybridization, 
loss of heterozygosity of the SDHB locus (Fig. 1C), 
and chromosome 1p fluorescence in situ hybridi-
zation all showed the loss of one 1p allele. These 
findings point to the biallelic inactivation of SDHB 
in this tumor: the mutation of one SDHB allele and 
the loss of the second SDHB allele. In addition, we 
found that there was an absence of SDHB expres-
sion in tumor cells, indicating complete loss of 
SDHB function (Fig. 1D and 1E).
We think it is likely that the somatic S100F 
mutation played a causal role in the tumorigene-
sis of the extraadrenal pheochromocytoma. Our 
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Figure 1. Molecular and Immunohistochemical Results. 
Sequencing chromatograms of SDHB exon 4 of tumor and normal DNA from the patient show the relative signal in-
tensities at position 299 of the wild-type nucleotide C and the substituted nucleotide T, indicating relative loss of the 
wild-type allele in the tumor DNA (Panel A). Panel B shows polymerase-chain-reaction–single-strand conformation 
polymorphism analysis of the patient’s normal (N) and tumor (T) DNA, as compared with control (C) DNA from a 
healthy subject. The aberrant migration pattern in the tumor DNA is apparent (arrowhead). In Panel C, the loss of 
heterozygosity is shown on an autoradiograph of chromosome 1p with a marker in proximity to the SDHB gene, in-
dicating relative loss of tumor DNA (arrowhead), as compared with the patient’s normal DNA and control DNA 
from a healthy subject. Immunohistochemical staining of the patient’s tumor for SDHB shows unstained tumor 
cells surrounded by endothelial cells with speckled staining (Panel D), in contrast to the staining pattern in a pheo-
chromocytoma without the SDHB mutation (Panel E). 
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findings suggest that the SDHB gene not only plays 
a role in the pathogenesis of a subgroup of inher-
ited pheochromocytomas but also can be involved 
in a subgroup of truly sporadic pheochromocy-
tomas.
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Dietary Supplement–Induced Vitamin D Intoxication
To the Editor: Vitamin D intoxication that is 
associated with the consumption of dietary sup-
plements is reported rarely.1 In 2004, the Food and 
Drug Administration (FDA) learned of the follow-
ing case.
A 58-year-old woman with diabetes mellitus 
and rheumatoid arthritis began taking a dietary 
supplement called Solutions IE Ageless Formula II 
on January 12, 2004. Fatigue, constipation, back 
pain, forgetfulness, nausea, and vomiting soon 
developed. On March 15, 2004, she was hospital-
ized because her speech was slurred, and a blood 
glucose reading taken at home was 30 mg per 
deciliter. On admission, her serum levels were as 
follows: calcium, more than 3.75 mmol per liter; 
25-hydroxyvitamin D, 1171 nmol per liter (normal 
range, 22 to 135); 1,25-dihydroxyvitamin D, 305 
pmol per liter (normal range, 36 to 144); parathy-
roid hormone, 12 ng per liter (normal range, 10 to 
65); calcitonin, 4.5 ng per liter (normal range, 
0 to 4.6); albumin, 31 g per liter; phosphorus, 
0.81 mmol per liter; blood urea nitrogen, 18.6 
mmol per liter; and creatinine, 265 μmol per liter.
The patient was treated with intravenous nor-
mal saline, furosemide, and pamidronate disodi-
um. On March 19, 2004, while still hospitalized, 
she was informed by the product distributor of an 
error in product formulation such that 188,640 IU 
of vitamin D3 had been added to the daily serving 
size of six capsules instead of the intended 400 IU. 
At discharge on March 24, the patient’s serum 
levels were as follows: calcium, 2.60 mmol per li-
ter; blood urea nitrogen, 10.0 mmol per liter; and 
creatinine, 221 μmol per liter. The patient died 
from a cause unknown to us on January 8, 2005.
Laboratory analysis of the product by the FDA, 
obtained from one of two lots reportedly over-
fortified with vitamin D3, revealed 186,906 IU of 
vitamin D3 in each serving size of six capsules, 
indicating that the patient had consumed rough-
ly 90 times the recommended safe upper limit of 
2000 IU per day. Long-term daily vitamin D con-
sumption of more than 40,000 IU (1000 μg) is 
needed to cause hypercalcemia in healthy per-
sons.2 In March 2004, the product distributor an-
nounced that during the previous month it had 
received three complaints from customers who 
had been hospitalized for hypercalcemia and 
vitamin D toxicity. The same month, the product 
manufacturer recalled 1600 bottles of the prod-
uct. The case described here underscores the need 
for the manufacturers of dietary supplements to 
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